tirzepatide lawsuits Eli Lilly sues Mochi Health and others for 'deceptive' marketing Novo sues Lilly, claiming misleading

A subset of patients may experience injection site reactions, including mild redness, itching, or tenderness at the injection site, though these are generally minor and resolve quickly

The drug could also aggravate pre-existing kidney concerns and in some cases, induce tumours in the thyroid, including thyroid cancer

For more on color expectations with B12 formulations, see what color tirzepatide with B12 should look like

Tirzepatide Tirzepatide is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist sometimes called a twincretin. GIP is a second gut hormone involved in insulin secretion, fat storage regulation, and energy metabolism

However, mass-marketed copycat products create different risks